Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aessopos, A.
Right arrow Articles by Karagiorga, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aessopos, A.
Right arrow Articles by Karagiorga, M.
(Chest. 2005;127:1523-1530.)
© 2005 American College of Chest Physicians

Thalassemia Heart Disease*

A Comparative Evaluation of Thalassemia Major and Thalassemia Intermedia

Athanasios Aessopos, MD, PhD; Dimitrios Farmakis, PhD; Spyros Deftereos, PhD; Maria Tsironi, PhD; Stergios Tassiopoulos, PhD; Ioannis Moyssakis, MD and Markisia Karagiorga, PhD

* From the First Department of Internal Medicine (Drs. Farmakis, Deftereos, Tsironi, Tassiopoulos, and Aessopos), University of Athens Medical School, "Laiko" General Hospital; Department of Cardiology (Dr. Moyssakis), "Laiko" Hospital; and Thalassemia Unit (Dr. Karagiorga), "Aghia Sophia" Children’s Hospital, Athens, Greece.

Correspondence to: Athanasios Aessopos, MD, PhD, First Department of Internal Medicine, "Laiko" General Hospital, 17 Aghiou Thoma St, Athens 115 27, Greece; e-mail: aaisopos{at}cc.uoa.gr; dfarm1{at}panafonet.gr

Background: Heart disease represents the main determinant of survival in ß-thalassemia, but its particular features in the two clinical forms of the disease, thalassemia major (TM) and thalassemia intermedia (TI), are not completely clarified.

Methods: We compared clinical and echocardiographic global parameters in 131 TM patients who received regular chelation transfusions and were highly compliant with treatment (mean age, 28 ± 6 years [± SD]), and 74 age-matched, TI patients who did not receive chelation transfusions.

Results: Congestive heart failure was encountered in five patients with TM (3.8%; age range, 25 to 29 years) and in two patients with TI (2.7%; age range, 37 to 40 years). Systolic left ventricular (LV) dysfunction (ejection fraction < 55% or shortening fraction < 35%) was only encountered in patients with TM (8.4%). Considerable pulmonary hypertension (systolic tricuspid gradient > 35 mm Hg) was only present in TI (23.0%). In the remaining patients without evident heart disease, cardiac dimensions, LV mass, LV shortening and ejection fractions, and cardiac output were significantly higher in patients with TI. LV afterload was higher in patients with TM. LV diastolic early transmitral diastolic peak flow velocity (E)/late transmitral diastolic peak flow velocity (A) ratio was also higher in TM. Systolic and mean pulmonary artery pressures and total pulmonary resistance were higher in both young and old TI patients.

Conclusion: Regular lifelong transfusion and chelation therapy in TM prevented premature heart disease and pulmonary hypertension, although LV dysfunction still occurred and led to heart failure. The absence of regular therapy in TI, in contrast, preserved systolic LV function but allowed pulmonary hypertension development, which also led to heart failure, starting within the fourth decade of life, a decade later compared to TM.

Key Words: deferoxamine • heart failure • iron chelation • pulmonary hypertension • thalassemia • transfusions




This article has been cited by other articles:


Home page
 HeartHome page
A Phrommintikul, A Sukonthasarn, R Kanjanavanit, and W Nawarawong
Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia
Heart, October 1, 2006; 92(10): 1467 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
A. AESSOPOS and D. FARMAKIS
Pulmonary Hypertension in {beta}-Thalassemia
Ann. N.Y. Acad. Sci., November 1, 2005; 1054(1): 342 - 349.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. T. Gladwin and G. J. Kato
Cardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia
Hematology, January 1, 2005; 2005(1): 51 - 57.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.